The composite autonomic symptom scale 31 is a useful screening tool for patients with Parkinsonism
Open Access
- 6 July 2017
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 12 (7) , e0180744
Abstract
Differentiation of multiple system atrophy with predominant parkinsonism (MSA-P) and Parkinson's disease (PD) is important, but an effective tool for differentiation has not been identified. We investigated the efficacy of the composite autonomic symptom scale 31 (COMPASS 31) questionnaire as a tool for evaluating autonomic function in parkinsonism patients. In this study, we enrolled drug-naïve patients with MSA-P and PD, and administered the COMPASS-31 and an objective autonomic dysfunction test (AFT). Demographic and clinical data, including parkinsonism and autonomic dysfunction, were compared between the two groups. Additionally, we determined the optimal COMPASS 31 cut-off score to differentiate MSA-P from PD for use as a screening tool. In this study, 27 MSA-P patients and 41 PD patients were recruited. The total COMPASS 31 score was well correlated with the objective AFT results. When we compared the COMPASS 31 score between the two groups, MSA-P patients showed higher total scores and sub-scores in the orthostatic intolerance, gastrointestinal, and bladder domains compared with PD patients. Similarly, MSA-P patients had more abnormalities in expiration to inspiration ratio, Valsalva ratio and pressure recovery time than PD patients in objective AFT. With 13.25 as the cut-off score for diagnosis of MSA-P, the total COMPASS-31 score demonstrated high sensitivity (92.6%) and moderate specificity (51.2%) with an area under the curve of 0.765. Based on our results, the COMPASS 31 is an effective tool for evaluation of autonomic function in patients with parkinsonism. The COMPASS-31 could be used as a sensitive and convenient screening tool, especially for the differentiation between MSA-P and PD.Keywords
This publication has 20 references indexed in Scilit:
- Cardiovascular Autonomic Dysfunction in Mild and Advanced Parkinson’s DiseaseJournal of Movement Disorders, 2016
- Autonomic symptom burden is associated with MS-related fatigue and quality of lifeMultiple Sclerosis and Related Disorders, 2015
- Cardiovascular autonomic testing performed with a new integrated instrumental approach is useful in differentiating MSA-P from PD at an early stageParkinsonism & Related Disorders, 2015
- Autonomic dysfunction according to disease progression in Parkinson's diseaseParkinsonism & Related Disorders, 2014
- COMPASS 31: A Refined and Abbreviated Composite Autonomic Symptom ScoreMayo Clinic Proceedings, 2012
- The role of autonomic testing in the differentiation of Parkinson's disease from multiple system atrophyJournal of the Neurological Sciences, 2012
- Comprehensive autonomic assessment does not differentiate between Parkinson’s disease, multiple system atrophy and progressive supranuclear palsyJournal of Neural Transmission, 2009
- Prospective Differentiation of Multiple System Atrophy From Parkinson Disease, With and Without Autonomic FailureArchives of Neurology, 2009
- Second consensus statement on the diagnosis of multiple system atrophyNeurology, 2008
- Autonomic nervous system testing may not distinguish multiple system atrophy from Parkinson's diseaseJournal of Neurology, Neurosurgery & Psychiatry, 2003